State Street Corp Purchases 63,002 Shares of AtriCure, Inc. (NASDAQ:ATRC)

State Street Corp raised its stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 4.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,344,856 shares of the medical device company's stock after buying an additional 63,002 shares during the period. State Street Corp owned approximately 2.76% of AtriCure worth $37,710,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Arizona PSPRS Trust acquired a new stake in shares of AtriCure during the third quarter worth $1,657,000. Atom Investors LP purchased a new position in AtriCure in the 3rd quarter worth about $1,741,000. PDT Partners LLC acquired a new stake in AtriCure during the 3rd quarter worth about $665,000. Captrust Financial Advisors purchased a new stake in AtriCure during the third quarter valued at about $230,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of AtriCure by 38.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,053 shares of the medical device company's stock worth $394,000 after buying an additional 3,880 shares during the period. Institutional investors own 99.11% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Oppenheimer boosted their price target on shares of AtriCure from $32.00 to $36.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. UBS Group boosted their target price on shares of AtriCure from $35.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Needham & Company LLC raised their target price on AtriCure from $34.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. reissued an "overweight" rating and set a $40.00 price target on shares of AtriCure in a research report on Tuesday. Finally, StockNews.com upgraded AtriCure from a "sell" rating to a "hold" rating in a research report on Saturday, September 14th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, AtriCure currently has an average rating of "Moderate Buy" and an average price target of $42.00.

AtriCure Stock Up 2.2 %

ATRC stock traded up $0.67 during mid-day trading on Friday, hitting $30.72. The stock had a trading volume of 666,504 shares, compared to its average volume of 694,920. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $39.04. The company has a fifty day moving average of $33.29 and a 200 day moving average of $27.51. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of -37.01 and a beta of 1.40.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. The firm had revenue of $115.91 million for the quarter, compared to the consensus estimate of $112.23 million. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. The firm's revenue was up 17.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.20) earnings per share. On average, equities analysts expect that AtriCure, Inc. will post -0.72 EPS for the current fiscal year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.